LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Elenco Azioni・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Chiusa

28.48 -3.29

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.7

Massimo

29.23

Metriche Chiave
By Trading Economics
Entrata	43M 13M
Vendite	29M 107M
EPS	0.25
Margine di Profitto	12.139
Dipendenti	524
EBITDA	16M 8.2M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+123.58% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	32M 1.5B
Apertura precedente	31.77
Chiusura precedente	28.48

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 giu 2026, 23:22 UTC

Utili

I principali Market Mover

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 giu 2026, 23:09 UTC

Azioni calde

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 giu 2026, 20:51 UTC

Utili

Costco Reports 15% Sales Growth in May

3 giu 2026, 20:43 UTC

Utili

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 giu 2026, 23:15 UTC

Discorsi di Mercato

Utili

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 giu 2026, 22:08 UTC

Azioni calde

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 giu 2026, 21:54 UTC

Discorsi di Mercato

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 giu 2026, 21:18 UTC

Utili

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 giu 2026, 21:15 UTC

Utili

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 giu 2026, 21:13 UTC

Utili

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 giu 2026, 21:13 UTC

Utili

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 giu 2026, 21:12 UTC

Utili

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 giu 2026, 21:09 UTC

Utili

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 giu 2026, 21:03 UTC

Utili

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 giu 2026, 20:43 UTC

Utili

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 giu 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 giu 2026, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 giu 2026, 20:35 UTC

Utili

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 giu 2026, 20:17 UTC

Utili

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 giu 2026, 20:17 UTC

Utili

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Adj EPS $2.44 >AVGO

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q EPS $1.91 >AVGO

3 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Rev $22.19B >AVGO

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

123.58% in crescita

Previsioni per 12 mesi

Media 65.13 USD 123.58%

Alto 100 USD

Basso 33 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.